Transmission of Clostridium difficile During Hospitalization for Allogeneic Stem Cell Transplant

Abstract

OBJECTIVE To determine the role of unit-based transmission that accounts for cases of early Clostridium difficile infection (CDI) during hospitalization for allogeneic stem cell transplant. SETTING Stem cell transplant unit at a tertiary care cancer center. METHODS Serially collected stool from patients admitted for transplant was screened for toxigenic C. difficile through the hospital stay and genotyping was performed by multilocus sequence typing. In addition, isolates retrieved from cases of CDI that occurred in other patients hospitalized on the same unit were similarly characterized. Transmission links were established by time-space clustering of cases and carriers of shared toxigenic C. difficile strains. RESULTS During the 27-month period, 1,099 samples from 264 patients were screened, 69 of which had evidence of toxigenic C. difficile; 52 patients developed CDI and 17 were nonsymptomatic carriers. For the 52 cases, 41 had evidence of toxigenic C. difficile on the first study sample obtained within a week of admission, among which 22 were positive within the first 48 hours. A total of 24 sequence types were isolated from this group; 1 patient had infection with the NAP1 strain. A total of 11 patients had microbiologic evidence of acquisition; donor source could be established in half of these cases. CONCLUSIONS Most cases of CDI after stem cell transplant represent delayed onset disease in nonsymptomatic carriers. Transmission on stem cell transplant unit was confirmed in 19% of early CDI cases in our cohort with a probable donor source established in half of the cases.

Reducing Clostridium difficile in the Inpatient Setting: A Systematic Review of the Adherence to and Effectiveness of C. difficile Prevention Bundles

“…54,55 While neither of these studies implemented a CDI bundle, they are otherwise similar to many of the studies that met our inclusion criteria. Our review sheds light on three potential reasons for a lack of decline in CDI rates.…”

Bacterial bloodstream infections in the allogeneic hematopoietic cell transplant patient: new considerations for a persistent nemesis

“…Recommendations for prevention of CVC-related infections, adopted from evidence-based guidelines Healthcare Infection Control Practices Advisory Committee 84 and the American Society of Clinical Oncology. 93 In 2011, the Healthcare Infection Control Practices Advisory Committee composed of members from professional organizations representing various major disciplines of healthcare created the 'Guidelines for the Prevention of Intravascular Cather-Related Infections'. 81 These recommendations included focusing on education of healthcare providers who place and maintain CVCs, utilization of sterile techniques in CVC insertion and maintenance and implementation of standardized bundled strategies to prevent infections.…”

“…In a recent study from MSKCC, rates of hospital-acquired CLABSI in high-risk adult patients including HCT recipients decreased by 34% to 2.3/1000 days after implementing a disinfection cap and resulted in substantial cost savings. 93 Prophylactic antibiotics According to recent BMT guidelines, fluoroquinolone prophylaxis should be considered for HCT patients with anticipated neutropenic periods of ⩾ 7 days. 94 Antibacterial prophylaxis is generally started at the time of hematopoietic cell infusion and continued until recovery from neutropenia or initiation of empirical antibacterial therapy for fever.…”

Clostridium difficile: The More We Learn, the Less We Know

“…23 While we lack full knowledge of the reservoirs of C. difficile, there is growing evidence that colonization in the community can lead to the subsequent development of C. difficile infection in the setting of antibiotic use, proton pump inhibitor use, or hospital admission. 18,[24][25][26] The current study by Kamboj et al 18 along with the earlier study by Eyre et al 19 demonstrate that current surveillance definitions and laboratory methods are too crude to accurately attribute C. difficile acquisition to a particular healthcare setting or inpatient unit. Failure to take into account the carrier state and to determine genetic relatedness of C. difficile strains leads to false attribution of C. difficile based on epidemiologic data alone.…”